Pharmacological examination of the neurokinin-1 receptor mediating relaxation of human intralobar pulmonary artery

Journal of Pharmacology and Experimental Therapeutics

Volumn 292, Issue 1, 2000, Pages 319-325

  Pedersen, Karen E ^a   Buckner, Carl K ^b   Meeker, Sonya N ^a   Undem, Bradley J ^a,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF PHARMACY   (United States)

^c JOHNS HOPKINS ASTHMA AND ALLERGY CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [1 IMINO 2 (2 METHOXYPHENYL)ETHYL] 7,7 DIPHENYLPERHYDROISOINDOL 4 ONE; 3 (2 METHOXYBENZYLAMINO) 2 PHENYLPIPERIDINE; 6 OXOPROSTAGLANDIN F1 ALPHA; INDOMETACIN; N BENZYL N2 [4 HYDROXY 1 [(1 METHYL 1H INDOL 3 YL)CARBONYL]PROLYL] N METHYL 3 (2 NAPHTHYL)ALANINAMIDE; N(G) NITROARGININE; NEUROKININ 1 RECEPTOR; NEUROKININ 1 RECEPTOR ANTAGONIST; NEUROKININ 3 RECEPTOR AGONIST; NEUROKININ A; NEUROKININ A [4-10][8 BETA ALANINE]; NOLPITANTIUM; PHENYLEPHRINE; SENKTIDE; SUBSTANCE P; SUBSTANCE P [6-11] DERIVATIVE;

ARTERY CONSTRICTION; ARTERY DILATATION; ARTICLE; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PULMONARY ARTERY; RECEPTOR AFFINITY; RECEPTOR BINDING; VASCULAR ENDOTHELIUM;

ADOLESCENT; ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENDOTHELIUM, VASCULAR; EPOPROSTENOL; FEMALE; HUMANS; LUNG; MALE; MIDDLE AGED; NEUROKININ A; NITRIC OXIDE; PEPTIDE FRAGMENTS; PHENYLEPHRINE; PULMONARY ARTERY; RECEPTORS, NEUROKININ-1; RECEPTORS, TACHYKININ; SUBSTANCE P; VASOCONSTRICTION; VASODILATION;

EID: 0033981790     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Aramori I, Morikawa N, Zenkoh J, O'Donnell N, Iwami M, Kojo H, Notsu Y, Okuhara M, Ono S and Nakanishi S (1994) Subtype- and species-selectivity of a tachykinin receptor antagonist, FK888, for cloned rat and human tachykinin receptors. Eur J Pharmacol 269:277-281.
2. Beattie DT, Stubs CM, Connor HE and Feniuk W (1993) Neurokinin-induced changes in pial artery diameter in the anesthetized guinea-pig. Br J Pharmacol 108:146-149.
3. Berthiaume N, Claing A, Regoli D, Warner TD and D'Orléans-Juste P (1995) Characterization of receptors for kinins and neurokinins in the arterial and venous mesenteric vasculatures of the guinea-pig. Br J Pharmacol 115:1319-1325.
4. Bodelsson G and Stjernquist M (1992) Smooth muscle dilation in the human uterine artery induced by Substance P, vasoactive intestinal polypeptide, calcitonin generelated peptide and atrial naturetic peptide: Relation to endothelium-derived relaxing substances. Hum Reprod 7:1185-1188.
5. Bodelsson G and Stjernquist M (1994) Endothelium-dependent relaxation to Substance P in human umbilical artery is mediated via prostanoid synthesis. Hum Reprod 9:733-737.
6. Bolton TB and Clapp LH (1986) Endothelial-dependent relaxant actions of carbachol and Substance P in arterial smooth muscle. Br J Pharmacol 87:713-723.
7. Canning BJ, Fischer A and Undem BJ (1998) Pharmacological analysis of the tachykinin receptors that mediate activation of nonadrenergic, noncholinergic relaxant nerves that innervate guinea pig trachealis. J Pharmacol Exp Ther 284:370-377.
8. Carruette A, Moussaoui SM, Champion A, Cottez D, Goniot P and Garret C (1992) Comparison in different tissue preparations of the in vitro pharmacological profile of RP 67580, a new non-peptide Substance P antagonist. Neuropeptides 4:245-250.
9. Cascieri MA, Macleod AM, Underwood D, Shiao L-L, Ber E, Sadowski S, Yu H, Merchant KJ, Swain CJ, Strader CD and Fong TM (1994) Characterization of the interaction of N-acyl-L-tryptophan benzyl ester neurokinin antagonists with the human neurokinin-1 receptor. J Biol Chem 269:6587-6591.
10. Constantine JW, Lebel WS and Woody HA (1991) Inhibition of tachykinin-induced hypotension in dogs by CP-96,345, a selective blocker of NK-1 receptors. Naunyn-Schmiedeberg's Arch Pharmacol 344:471-477.
11. Corboz MR, Rivelli MA, Ramos SI, Rizzo CA and Hey JA (1998) Tachykinin NK1 receptor-mediated vasorelaxation in human pulmonary arteries. Eur J Pharmacol 350:R1-3.
12. Croci T, Emonds-Alt X, LeFur J and Manara L (1995) In vitro characterization of the non-peptide tachykinin NK1 and NK2-receptor antagonists, SR140333 and SR48968 in different rat and guinea-pig intestinal segments. Life Sci 56:267-275.
13. D'Orléans-Juste P, Dion S, Mizrahi J and Regoli D (1985) Effects of peptides and non-peptides in isolated arterial smooth muscles: Role of endothelium. Eur J Pharmacol 114:9-21.
14. Ellis JE, Sham J and Undem BJ (1997) Tachykinin-independent effects of capsaicin on smooth muscle tone in human isolated bronchi. Am J Respir Crit Care Med 155:751-755.
15. Enokibori M, Okamura T and Toda N (1994) Mechanism underlying Substance P-induced relaxation in dog isolated superficial temporal arteries. Br J Pharmacol 111:77-82.
16. Fong TM, Huang R-RC and Strader CD (1992a) Localization of agonist and antagonist binding domains of the human neurokinin-1 receptor. J Biol Chem 267: 25664-25667.
17. Fong TM, Yu H and Strader CD (1992b) Molecular basis for the species selectivity of the neurokinin-1 receptor antagonists CP-96,345 and RP67580. J Biol Chem 267:25668-25671.
18. Hall JM and Brain SD (1994) Inhibition of SR 140333 of NK1 tachykinin receptor-evoked, nitric oxide-dependent vasodilatation in the hamster cheek pouch microvasculature in vivo. Br J Pharmacol 113:522-526.
19. Hall JM, Mitchell D and Morton IK (1994) Typical and atypical NK1 tachykinin receptor characteristics in the rabbit isolated iris sphincter. Br J Pharmacol 112:985-991.
20. Hosoki R, Yanagisawa M, Onishi Y, Yoshioka K and Otsuka M (1998) Pharmacological profiles of new orally active nonpeptide tachykinin NK1 receptor antagonists. Eur J Pharmacol 341:235-241.
21. Hubbard WC, Litterst CC, Liu MC, Bleecker ER, Eggleston PC, McLemore TC and Boyd MR (1986) Profiling of prostaglandin biosynthesis in biopsy fragments of human lung carcinoma and normal human lung by capillary gas chromatography-negative ion chemical ionization mass spectrometry. Prostaglandins 32:889-906.
22. Landino LM, Crews BC, Timmons MD, Morrow JD and Marnett LJ (1996) Peroxynitrite, the coupling product of nitric oxide and superoxide, activates prostaglandin biosynthesis. Proc Natl Acad Sci USA 93:15069-15074.
23. Maggi CA, Patacchini R, Perretti F, Tranontana M, Manzini S, Geppetti P and Santicioli P (1990) Sensory nerves, vascular endothelium and neurogenic relaxation of the guinea-pig isolated pulmonary artery. Naunyn-Schmiedeberg's Arch Pharmacol 342:78-84.
24. Maggi CA and Schwartz TW (1997) The dual nature of the tachykinin NK1 receptor. Trends Pharmacol Sci 18:351-355.
25. McCormack DG, Salonen RP and Barnes PJ (1989) Effect of sensory neuropeptides on canine bronchial and pulmonary vessels in vitro. Life Sci 45:2405-2412.
26. McEwan JR, Benjamin N, Larkin S, Fuller RW, Dollery CT and MacIntyre I (1988) Vasodilatation by calcitonin gene-related peptide and by Substance P: A comparison of their effects on resistance and capacitance vessels of human forearms. Circulation 77:1072-1080.
27. McLean S, Ganong A, Seymour PA, Snider RM, Desai MC, Rosen T, Bryce DK, Longo KP, Reynolds LS, Robinson G, Schmidt AW, Siok C and Heym J (1993) Pharmacology of CP-99,994; a nonpeptide antagonist of the tachykinin neurokinin-1 receptor. J Pharmacol Exp Ther 267:472-479.
28. Nsa Allogho S, Nguyen-Le XK, Gobeil F, Pheng LH and Regoli D (1997) Neurokinin receptors (NK1, NK2) in the mouse: A pharmacological study. Can J Physiol Pharmacol 75:552-557.
29. Onoue H, Kaito N, Tomii M, Tokudome S, Nakajima M and Abe T (1994) Human basilar and middle cerebral arteries exhibit endothelium-dependent responses to peptides. Am J Physiol 267:H880-H886.
30. Petersson J, Zygmut PM, Brandt L and Högestätt ED (1995) Substance P-induced relaxation and hyperpolarization in human cerebral arteries. Br J Pharmacol 115:889-894.
31. Rosenblum WI, Shimizu T and Nelson GH (1993) Endothelium-dependent effects of Substance P and calcitonin gene-related peptide on mouse pial arterioles. Stroke 24:1043-1048.
32. Salvemini D, Misko TO, Masferrer JL, Seibert K, Currie MG and Needleman P (1993) Nitric oxide activates cyclooxygenase enzymes. Proc Natl Acad Sci USA 90:7240-7244.
33. Sautebin J, Ialenti A, Ianaro A and DiRosa M (1995) Modulation by nitric oxide of prostaglandin biosynthesis in the rat. Br J Pharmacol 114:323-328.
34. Shirahase H, Kanda M, Kurahashi K, Nakamura S, Usui H and Shimizu Y (1995) Endothelium-dependent contraction in intrapulmonary arteries: Mediation by endothelial NK1 receptors and TXA2. Br J Pharmacol 115:1215-1220.
35. Strobel WM, Lüscher FL, Simper D, Linder L and Haefeli WE (1996) Substance P in human hand veins in vivo: Tolerance, efficacy, potency, and mechanism of venodilator action. Clin Pharmacol Ther 60:435-443.
36. Toda N, Kawakami M, Yamazaki M and Okamura T (1991) Comparison of endothelium-dependent responses of monkey cerebral and temporal arteries. Br J Pharmacol 102:805-810.
37. Wallerstedt SM and Bodelsson M (1997) Endothelium-dependent relaxation by Substance P in human isolated ometal arteries and veins: Relative contribution of prostanoids, nitric oxide and hyperpolarization. Br J Pharmacol 120:25-30.
38. Walpole CS, Brown MC, James IF, Campbell EA, McIntyre P, Docherty R, Ko S, Hedley L, Ewan S, Buchheit KH and Urban LA (1998) Comparative, general pharmacology of SDZ NKT 343, a novel, selective NK1 receptor antagonist. Br J Pharmacol 124:83-92.